Thoracoscopic Versus Catheter Ablation in Persistent Atrial Fibrillation With Enlarged Left Atrium
Endocardial Catheter Ablation Versus Thoracoscopic Ablation in De Novo Persistent Atrial Fibrillation Patients With Enlarged Left Atrium: A Randomized Controlled Trial
This is a prospective, single-center, open-label, randomized controlled trial comparing thoracoscopic surgical ablation with percutaneous endocardial catheter ablation as the first rhythm-control procedure in patients with persistent atrial fibrillation and an enlarged left atrium (LA diameter ≥50 mm or LA volume index ≥45 mL/m²).
A total of 194 patients who have never undergone an ablation procedure for atrial fibrillation will be randomly assigned 1:1 to thoracoscopic ablation or percutaneous catheter ablation, stratified by duration of atrial fibrillation. The primary endpoint is recurrence of atrial tachyarrhythmia (atrial fibrillation, atrial flutter, or atrial tachycardia) after a 3-month blanking period. The investigators hypothesize that thoracoscopic ablation will significantly reduce recurrence compared with catheter ablation in this population.
A secondary hypothesis is that 14-day patch monitoring detects recurrent atrial tachyarrhythmia more sensitively than conventional 24-hour Holter monitoring.
연구 개요
상태
상세 설명
Pulmonary vein isolation is an established rhythm-control therapy for symptomatic atrial fibrillation refractory to antiarrhythmic drugs. Its efficacy is lower in persistent than in paroxysmal atrial fibrillation, and additional substrate modification of the left atrium is frequently required.
Percutaneous catheter ablation (radiofrequency, cryoballoon or PFA) and thoracoscopic surgical ablation are both used in current practice. Thoracoscopic ablation additionally allows epicardial pulmonary vein isolation, ganglionated plexi ablation, dissection of the ligament of Marshall, and left atrial appendage exclusion, at the cost of a longer hospital stay and a higher incidence of post-procedural pericarditis. Recent trials have shown broadly comparable efficacy and safety between the two approaches, so both are used interchangeably in practice.
In a retrospective analysis of the institutional ablation registry at the study site, overall outcomes of the two strategies were comparable, but among patients with an enlarged left atrium thoracoscopic ablation was associated with significantly lower recurrence of atrial tachyarrhythmia. Because that finding came from a subgroup of a retrospective cohort, it could not support a firm conclusion.
This trial therefore prospectively tests, in patients with persistent atrial fibrillation and an enlarged left atrium undergoing a first rhythm-control procedure, whether thoracoscopic ablation is superior to percutaneous catheter ablation.
Post-procedural management is identical in both arms: a 3-month blanking period, discontinuation of antiarrhythmic drugs at 3 months (up to 6 months) if sinus rhythm is maintained, and anticoagulation for at least 3 months with subsequent decisions based on recurrence, prior stroke, and CHA2DS2-VASc score. Follow-up visits occur at 3, 6, and 12 months and every 6 months thereafter until 1 year after the last patient is enrolled. Rhythm monitoring uses 12-lead ECG, 24-hour Holter (3, 6, 12 months), and 14-day patch monitoring; echocardiography and NT-proBNP are obtained at baseline, 12 months, and annually thereafter.
연구 유형
등록 (추정된)
단계
- 해당 없음
연락처 및 위치
연구 연락처
- 이름: Young Keun On, MD, PhD
- 전화번호: +82-2-3410-2578
- 이메일: yk.on@samsung.com
연구 장소
-
-
Seoul
-
Seoul, Seoul, 대한민국, 06351
- 모병
- Samsung Medical Center
-
연락하다:
- Young Keun On, MD, PhD
- 전화번호: +82-2-3410-2578
- 이메일: yk.on@samsung.com
-
연락하다:
- 이메일: abcd186a@naver.com
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
설명
Inclusion Criteria:
- Age 19 years or older
- Persistent atrial fibrillation refractory to antiarrhythmic drug therapy, or in whom antiarrhythmic drug therapy cannot be maintained
- European Heart Rhythm Association (EHRA) symptom score ≥ 2
- Considered suitable for rhythm-control therapy by either percutaneous catheter ablation or thoracoscopic ablation, at the investigator's medical discretion
- Enlarged left atrium, defined as left atrial diameter ≥ 50 mm or left atrial volume index ≥ 45 mL/m²
Exclusion Criteria:
- Previous percutaneous catheter ablation or thoracoscopic ablation for atrial fibrillation
- Previous thoracic or cardiac surgery
- Absolute contraindication to anticoagulation therapy
- Life expectancy less than 1 year due to non-cardiac disease, or anticipated poor adherence to treatment, at the investigator's medical discretion
- Refusal to participate in the study
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Thoracoscopic ablation
Thoracoscopic surgical ablation is performed according to the standard technique.
Pulmonary vein isolation and left atrial appendage exclusion are mandatory.
Additional lesions are at the operator's discretion.
|
Thoracoscopic surgical ablation is performed according to the standard technique.
Pulmonary vein isolation and left atrial appendage exclusion are mandatory.
Additional lesions are at the operator's discretion.
|
|
활성 비교기: Percutaneous catheter ablation
Percutaneous endocardial catheter ablation is performed using radiofrequency, cryoballoon, or pulsed field energy.
Pulmonary vein isolation is mandatory.
Additional lesions are at the operator's discretion.
|
Percutaneous endocardial catheter ablation is performed using radiofrequency, cryoballoon, or pulsed field energy.
Pulmonary vein isolation is mandatory.
Additional lesions are at the operator's discretion.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Recurrence of atrial tachyarrhythmia
기간: From 3 months after the index procedure until 1 year after enrollment of the last patient
|
Recurrence of atrial fibrillation, atrial flutter, or atrial tachycardia, defined as an episode documented on 12-lead ECG or sustained for at least 30 seconds on continuous monitoring (14-day patch monitor or 24-hour Holter).
Recurrences during the 3-month blanking period are not counted as events.
|
From 3 months after the index procedure until 1 year after enrollment of the last patient
|
2차 결과 측정
결과 측정 |
기간 |
|---|---|
|
Recurrence of atrial fibrillation
기간: From 3 months after the index procedure until 1 year after enrollment of the last patient
|
From 3 months after the index procedure until 1 year after enrollment of the last patient
|
|
Recurrence of atrial flutter
기간: From 3 months after the index procedure until 1 year after enrollment of the last patient
|
From 3 months after the index procedure until 1 year after enrollment of the last patient
|
|
Recurrence of atrial tachycardia
기간: From 3 months after the index procedure until 1 year after enrollment of the last patient
|
From 3 months after the index procedure until 1 year after enrollment of the last patient
|
|
All-cause death
기간: From 3 months after the index procedure until 1 year after enrollment of the last patient
|
From 3 months after the index procedure until 1 year after enrollment of the last patient
|
|
Cardiac death
기간: From 3 months after the index procedure until 1 year after enrollment of the last patient
|
From 3 months after the index procedure until 1 year after enrollment of the last patient
|
|
Stroke
기간: From 3 months after the index procedure until 1 year after enrollment of the last patient
|
From 3 months after the index procedure until 1 year after enrollment of the last patient
|
|
Hospitalization for heart failure
기간: From 3 months after the index procedure until 1 year after enrollment of the last patient
|
From 3 months after the index procedure until 1 year after enrollment of the last patient
|
|
Procedure-related complications
기간: From 3 months after the index procedure until 1 year after enrollment of the last patient
|
From 3 months after the index procedure until 1 year after enrollment of the last patient
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- SMC 2023-06-103
- KCT0009360 (기타 식별자: Korea National Institute of Health)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .